Pregnancy and post-partum breast cancer: A prospective study

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2447-2452

  Mathelin, Carole ^a,b   Annane, Kadour ^a   Treisser, Alain ^c   Chenard, Marie Pierre ^d   Tomasetto, Catherine ^b   Bellocq, Jean Pierre ^d   Rio, Marie Christine ^b  

^a HÔPITAL CIVIL   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^d HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Breast cancer; Child outcome; Hormonotherapy; Patient outcome; Pregnancy

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROTEIN PS2; TAMOXIFEN;

AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CANCER SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREGNANCY; PREGNANCY ASSOCIATED BREAST CANCER; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 48849086006     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Porta RP, Franco C, Cosmi EV, Montruccoli G and Cavazzana AO: Pregnancy-associated breast cancer. Breast J 10(2): 169, 2004.
2. Kahlert S, Bauerfeind I, Strauss A and Untch M: Breast cancer treatment during pregnancy - experiences in the department of OB/GYN Grosshadern-Munich and review of international data. Zentralbl Gynakol 126(3): 159-166, 2004.
3. Theriault R and Hahn K: Management of breast cancer in pregnancy. Curr Oncol Rep 9(1): 17-21, 2007.
4. Elledge RM, Ciocca DR, Langone G and McGuire WL: Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 71(8): 2499-2506, 1993.
5. Shousha S: Breast carcinoma presenting during or shortly after pregnancy and lactation. Arch Pathol Lab Med 124(7): 1053-1060, 2000.
6. Bonnier P, Romain S, Dilhuydy JM, Bonichon F, Julien JP, Charpin C et al: Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 72(5): 720-727, 1997.
7. Reed W, Hannisdal E, Skovlund E, Thoresen S, Lilleng P and Nesland JM: Pregnancy and breast cancer: a population-based study. Virchows Arch 443(1): 44-50, 2003.
8. Polyak K: Pregnancy and breast cancer: the other side of the coin. Cancer Cell 9(3): 151-153, 2006.
9. Man W, Kim SW, Park IA, Kang D, Kim SW, Youn YK et al: Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4: 82, 2004.
10. Woo JC, Yu T and Kurd TC: Breast cancer in pregnancy: a literature review. Arch Surg 138(1): 91-98, 2003.
11. Sanchez-Barcelo EJ, Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A and Alonso-Gonzalez C: Melatonin-estrogen interactions in breast cancer. J Pineal Res 38(4): 217-222, 2005.
12. Tworoger SS and Hankinson SE: Prolactin and breast cancer risk. Cancer Lett 243(2): 160-169, 2006.
13. Clevenger CV: Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis 18: 75-86, 2003.
14. Russo J, Mailo D, Hu YF, Balogh G, Sheriff F and Russo IH: Breast differentiation and its implication in cancer prevention. Clin Cancer Res 11(2 Pt 2): 931s-936s, 2005.
15. Russo J, Moral R, Balogh GA, Mailo D and Russo IH: The protective role of pregnancy in breast cancer. Breast Cancer Res 7(3): 131-142, 2005.
16. Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P and Grenier J: Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 83(4): 698-705, 1998.
17. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F and Brunei M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1,262 invasive ductal breast carcinomas. Cancer 64(9): 1914-1921, 1989.
18. Thike AA, Chng MJ, Fook-Chong S and Tan PH: Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology 33(1): 21-25, 2001.
19. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G et al: Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13(2): 273-279, 2002.
20. Ribieras S, Tomasetto C and Rio MC: The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta 1378(1): F61-77, 1998.
21. Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C et al: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 84(24): 9243-9247, 1987.
22. Lelle RJ, Henkel E, Leinemann D and Goeschen K: Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest 27(3): 137-142, 1989.
23. Rio MC: From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. Biochimie 87(3-4): 299-306, 2005.
24. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W et al: Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 168(2): 608-620, 2006.
25. Annane K, Bellocq JP, Brettes JP and Mathelin C: Infiltrative breast cancer during pregnancy and conservative surgery. Fetal Diagn Ther 20(5): 442-444, 2005.
26. Peccatori F, Martinelli G, Gentilini O and Goldhirsch A: Chemotherapy during pregnancy: what is really safe? Lancet Oncol 5(7): 398, 2004.
27. Mathelin C, Annane K, Dufour P, Liegeois P and Bergerat JP: Chemotherapy for breast cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol 123(2): 260-262, 2005.
28. Loibl S, von Minckwitz G, Gwyn K, Ellis P, Blohmer JU, Schlegelberger B et al: Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 106(2): 237-246, 2006.
29. Nugent P and O'Connell TX: Breast cancer and pregnancy. Arch Surg 120(11): 1221-1224, 1985.
30. Spyratos F, Andrieu C, Hacene K, Chambon P and Rio MC: pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 69(2): 394-397, 1994.
31. Ruibal A, Schneider J, del Rio C, Arias J, Nunez MJ, Piqueras V et al: pS2 negativity in postmenopausal women with ER+PgR+ infiltrating ductal breast carcinoma is associated with reduced hormone dependence and increased proliferation and aneuploidy of the tumors. Int J Biol Markers 14(3): 186-188, 1999.
32. http://www.ined.fr/fr/pop_chiffres/france/naissances_fecondite/ naissances_par_sexe/: Institut national d'études démographiques, 22 Janvier 2008.
33. Hsieh C, Wuu J, Trichopoulos D, Adami HO and Ekbom A: Gender of offspring and maternal breast cancer risk. Int J Cancer 81(3): 335-338, 1999.